US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

11.41

-0.7500-6.17%

Volume:120.33K

Turnover:1.40M

Market Cap:561.92M

PE:-2.53

High:12.85

Open:12.26

Low:11.21

Close:12.16

52wk High:17.82

52wk Low:8.75

Shares:49.25M

Float Shares:13.84M

Volume Ratio:0.99

T/O Rate:0.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:5.30

PE(LYR):-0.07

Loading ...

Overview Company News Filings

Press Release: Agomab Announces Results of Annual General Meeting

Wall Street Analysts Are Bullish on Top NA Picks

Press Release: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab FY25 net loss widens 35% to EUR 62.5 million

Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041

Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/AGMB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":11.41,"timestamp":1789588800000,"preClose":12.16,"halted":0,"volume":120333,"delay":0,"changeRate":-0.061677631578947366,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Pre-Mkt","change":-0.75,"latestTime":"09-17 04:38:28 EDT","open":12.26,"high":12.845,"low":11.21,"amount":1400768.656077,"amplitude":0.134457,"askPrice":18.14,"askSize":100,"bidPrice":8.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.41,"postHourTrading":{"tag":"盘后","latestPrice":11.41,"preClose":11.41,"latestTime":"19:30 EDT","volume":263,"amount":3005.33,"timestamp":1789601404503,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.988497797633265},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.988497797633265,"shares":49248000,"dividePrice":0,"high":12.845,"amplitude":0.134457,"preClose":12.16,"low":11.21,"week52Low":8.75,"pbRate":"5.30","week52High":17.82,"institutionHeld":0,"latestPrice":11.41,"eps":-4.51426,"divideRate":0,"volume":120333,"delay":0,"ttmEps":-4.51426,"open":12.26,"prevYearClose":16,"prevWeekClose":13.06,"prevMonthClose":13.17,"prevQuarterClose":12.98,"fiveDayClose":14.96,"twentyDayClose":13.73,"sixtyDayClose":11.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-16","current":-2.527546,"percent":0.821192,"low":-14.725744,"twenty":-11.715841,"median":-8.911516,"eighty":-7.864702,"high":-6.52172,"avg":-9.579591,"sd":2.184566,"marketCap":598855376},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-16","current":-7.786468,"twenty":-11.715841,"median":-8.911516,"eighty":-7.864702,"marketCap":598855376}],"updateTime":1789634308988},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638950336","title":"Press Release: Agomab Announces Results of Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638950336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638950336?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:00","pubTimestamp":1779872400,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, May 27, 2026 -- Agomab Therapeutics NV  , a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting  held on Tuesday, May 26, 2026.-- Approval of the statutory financial statements for the financial year. -- Discharge to the current and former members of the Board of Directors and. the statutory auditor in respect of the performance of their respective. duties during the financial year ending on December 31, 2025.-- Reappointment of Mr. Ohad Hammer as a member of the Board of Directors. -- Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab's product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGM","BK4007","BK4195","BK4229","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076558","title":"Wall Street Analysts Are Bullish on Top NA Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076558?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:01","pubTimestamp":1779109297,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on AgomAb Therapeutics NV ADR (AGMB) and Standard Chartered (SC...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSX","BLSG","BK4112","SCBFY","AGMB","BK4007","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629690438","title":"Press Release: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2629690438","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629690438?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:14","pubTimestamp":1776982440,"startTime":"0","endTime":"0","summary":"-- Cash and Cash Investments at December 31, 2025 of EUR116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering  Expected to Extend Cash Runway into First Half of 2029 --. Pierre Kemula, Chief Financial Officer of Agomab, added, \"Thanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IPO","BK4229","AGM","BK4195","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629866477","title":"Agomab FY25 net loss widens 35% to EUR 62.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629866477","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629866477?lang=en_us&edition=fundamental","pubTime":"2026-04-24 05:18","pubTimestamp":1776979127,"startTime":"0","endTime":"0","summary":"Agomab posted a net loss of EUR 62.5 million for fiscal 2025, widening 35%.Operating loss widened 23% to EUR 59.3 million.Research and development expenses climbed 24% to EUR 48.9 million, due to progress in clinical testing for ontunisertib and AGMB-447.Other operating income jumped 68% to EUR 2.4 million.Cash, cash equivalents and cash investments totaled EUR 116.5 million at Dec. 31, 2025; existing liquidity plus IPO proceeds expected to fund operations into the first half of 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLbZTC6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622085155","title":"Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2622085155","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622085155?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:01","pubTimestamp":1774522892,"startTime":"0","endTime":"0","summary":"Agomab said the USPTO granted U.S. Patent No. 12,577,230 covering the composition of matter of AGMB-447.AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5  in a Phase 1b study for idiopathic pulmonary fibrosis.The company said the patent provides U.S. IP protection through at least 2041, excluding potential patent term extensions.CEO Tim Knotnerus said Agomab expects results from the idiopathic pulmonary fibrosis patient cohort of the Phase 1b study later this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2yYlHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014013.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","AGMB","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4007","LU0314104364.USD","SG9999014039.USD","LU2210149790.SGD","SG9999014005.SGD","BK4588","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","IE00BN0W2T93.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622212859","title":"Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622212859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622212859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA6BRHW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851262","title":"Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851262?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262841/0/en/Agomab-Receives-U-S-Patent-for-AGMB-447-its-Inhaled-Lung-restricted-Small-Molecule-Inhibitor-of-ALK5-in-Development-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU1481600234.SGD","IP","IE00B3T34201.USD","BK4588","LU1169590202.USD","LU1487256676.USD","AGMB","BK4585","LU2463526074.USD","BK4007","BK4136","LU1481599808.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":47,"code":"91000000","status":"200"}]}}